Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 18, 2011 06:30 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Advances Its Preclinical Research Program For The Use Of Guanylate Cyclase C Agonists To Lower Cholesterol

NEW YORK--Synergy Pharmaceuticals, Inc. (OTCQB:SGYP.PK), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has successfully completed preclinical...
May 03, 2011 08:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at Bank of America Merrill Lynch Health Care Conference

NEW YORK--Synergy Pharmaceuticals, Inc. (OTC QB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced that Dr. Gary S. Jacob, President and Chief Executive...
March 22, 2011 08:15 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Appoints Dr. Laura Barrow as Vice President of Clinical Operations

NEW YORK--Synergy Pharmaceuticals, Inc. (OTCQB:SGYP.OB), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the appointment of Laura Barrow, Pharm. D. as...
March 08, 2011 08:15 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at BIO-Europe Spring 2011 Conference

BIO-Europe Spring 2011 NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that Dr. Gary S. Jacob,...
February 23, 2011 05:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Granted U.S. Patent on SP-333, Synergy's Developmental Drug for Gastrointestinal Inflammatory Diseases

NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and...
February 07, 2011 10:20 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at the 13th Annual BIO CEO and Investor Conference

BIO CEO & Investor Conference 2011 NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that...
January 07, 2011 08:00 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Announces New Clinical Development Plan for Plecanatide

NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the next clinical trial of plecanatide to...
November 04, 2010 15:35 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Awarded Federal Grant to Support Further Development of Plecanatide to Treat Gastrointestinal Disorders

NEW YORK--Synergy Pharmaceuticals, Inc. (OTC BB: SGYP), a developer of new drugs to treat gastrointestinal disorders (GI) and diseases, announced today that it has been awarded a $244,479 grant under...
October 06, 2010 07:15 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals Announces Positive Phase IIa Results with Plecanatide to Treat Chronic Constipation

NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB: SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today positive results in a Phase IIa clinical trial of...
September 14, 2010 07:15 ET | Source: Synergy Pharmaceuticals

Synergy Pharmaceuticals to Present at Roche Colorado Corporation Peptide Symposium 2010

NEW YORK--Synergy Pharmaceuticals, Inc. (OTCBB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that Dr. Kunwar Shailubhai, the Company’s Chief...